Current status of the HIBMC and results of representative diseases

Murakami, Masao; Demizu, Yusuke; Niwa, Yasue; Miyawaki, Daisuke; Terashima, Kazuki; Arimura, Takeshi; Mima, Masayuki; Maeda, Takuya; Akagi, Takashi; Hishikawa, Yoshio; Abe, Mitsuyuki; Nagayama, Shinichi; Baba, Masashi

doi:10.1063/1.3204552

Title: Current status of the HIBMC and results of representative diseases

Full Record
Other Related Research

Abstract

The proton radiotherapy (PRT) has been spreading, since 1990 when 250 MeV proton beams with rotation gantry was developed for medical use. On the other hand, carbon-ion radiotherapy (CRT) that has both physical and biological features is available at 4 facilities in the world. HIBMC is the only facility to be able to use both particles. From Apr 2001 to Dec 2008, 2486 patients were treated with PRT in 2030 patients or with CRT in 456. Treatment to the Head and Neck (H and N: in 405 patients), the lung (245), the liver (371), and the prostatic carcinoma (1059) was a major subject. The 2-year local control rates is 72% in H and N (n = 163, T1:9, T2:18, T3:36, T4:79, malignant melanoma 48, adenoid cystic carcinoma 35, squamous cell carcinoma (SCC) 32, adenocarcinoma 14, others 34), 88% in lung (n = 116, T1:59, T2:42, T3:4, T4:6, SCC 30, adenocarcinoma 59, others 27), and 89% in liver cancer (n = 153, Proton: 130, carbon: 23). Biochemical disease free 3-year survival of 291 prostate cancer is 100% in 9 patients with initial prostate-specific antigen (PSA) level < = 4 ng/ml, 99% in 140 with PSA 4.1-10 ng/ml, 90% in 71 withmore »« less

Authors:

Murakami, Masao; Demizu, Yusuke; Niwa, Yasue; Miyawaki, Daisuke; Terashima, Kazuki; Arimura, Takeshi; Mima, Masayuki; Maeda, Takuya; Akagi, Takashi; Hishikawa, Yoshio; Abe, Mitsuyuki ^[1]; Nagayama, Shinichi; Baba, Masashi ^[1]

Department of Radiology, Hyogo Ion Beam Medical Center (HIBMC) (Japan)

Publication Date:: Sat Jul 25 00:00:00 EDT 2009

OSTI Identifier:: 21344336

Resource Type:: Journal Article

Journal Name:: AIP Conference Proceedings

Additional Journal Information:: Journal Volume: 1153; Journal Issue: 1; Conference: 2. international symposium on laser-driven relativistic plasmas applied to science, industry and medicine, Kyoto (Japan), 19-23 Jan 2009; Other Information: DOI: 10.1063/1.3204552; (c) 2009 American Institute of Physics; Journal ID: ISSN 0094-243X

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIGENS; CARBON IONS; CLINICAL TRIALS; COMPARATIVE EVALUATIONS; HEAD; ION BEAMS; LIVER; LUNGS; MELANOMAS; MEV RANGE; NECK; PATIENTS; PROSTATE; PROTON BEAMS; RADIOTHERAPY; BEAMS; BODY; CARCINOMAS; CHARGED PARTICLES; DIGESTIVE SYSTEM; DISEASES; ENERGY RANGE; EPITHELIOMAS; EVALUATION; GLANDS; IONS; MALE GENITALS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEON BEAMS; ORGANS; PARTICLE BEAMS; RADIOLOGY; RESPIRATORY SYSTEM; TESTING; THERAPY

Citation Formats


                    Murakami, Masao, Demizu, Yusuke, Niwa, Yasue, Miyawaki, Daisuke, Terashima, Kazuki, Arimura, Takeshi, Mima, Masayuki, Maeda, Takuya, Akagi, Takashi, Hishikawa, Yoshio, Abe, Mitsuyuki, Nagayama, Shinichi, Baba, Masashi, and Shin Nippon Biomedical Laboratories, Ltd. Current status of the HIBMC and results of representative diseases.  United States: N. p., 2009. 
        Web.  doi:10.1063/1.3204552.

Copy to clipboard


                    Murakami, Masao, Demizu, Yusuke, Niwa, Yasue, Miyawaki, Daisuke, Terashima, Kazuki, Arimura, Takeshi, Mima, Masayuki, Maeda, Takuya, Akagi, Takashi, Hishikawa, Yoshio, Abe, Mitsuyuki, Nagayama, Shinichi, Baba, Masashi, & Shin Nippon Biomedical Laboratories, Ltd. Current status of the HIBMC and results of representative diseases.  United States.  https://doi.org/10.1063/1.3204552

Copy to clipboard


                    Murakami, Masao, Demizu, Yusuke, Niwa, Yasue, Miyawaki, Daisuke, Terashima, Kazuki, Arimura, Takeshi, Mima, Masayuki, Maeda, Takuya, Akagi, Takashi, Hishikawa, Yoshio, Abe, Mitsuyuki, Nagayama, Shinichi, Baba, Masashi, and Shin Nippon Biomedical Laboratories, Ltd. 2009.  
        "Current status of the HIBMC and results of representative diseases".  United States.  https://doi.org/10.1063/1.3204552.

Copy to clipboard


                    
@article{osti_21344336,

  title        = {Current status of the HIBMC and results of representative diseases},

  author       = {Murakami, Masao and Demizu, Yusuke and Niwa, Yasue and Miyawaki, Daisuke and Terashima, Kazuki and Arimura, Takeshi and Mima, Masayuki and Maeda, Takuya and Akagi, Takashi and Hishikawa, Yoshio and Abe, Mitsuyuki and Nagayama, Shinichi and Baba, Masashi and Shin Nippon Biomedical Laboratories, Ltd.},

  abstractNote = {The proton radiotherapy (PRT) has been spreading, since 1990 when 250 MeV proton beams with rotation gantry was developed for medical use. On the other hand, carbon-ion radiotherapy (CRT) that has both physical and biological features is available at 4 facilities in the world. HIBMC is the only facility to be able to use both particles. From Apr 2001 to Dec 2008, 2486 patients were treated with PRT in 2030 patients or with CRT in 456. Treatment to the Head and Neck (H and N: in 405 patients), the lung (245), the liver (371), and the prostatic carcinoma (1059) was a major subject. The 2-year local control rates is 72% in H and N (n = 163, T1:9, T2:18, T3:36, T4:79, malignant melanoma 48, adenoid cystic carcinoma 35, squamous cell carcinoma (SCC) 32, adenocarcinoma 14, others 34), 88% in lung (n = 116, T1:59, T2:42, T3:4, T4:6, SCC 30, adenocarcinoma 59, others 27), and 89% in liver cancer (n = 153, Proton: 130, carbon: 23). Biochemical disease free 3-year survival of 291 prostate cancer is 100% in 9 patients with initial prostate-specific antigen (PSA) level < = 4 ng/ml, 99% in 140 with PSA 4.1-10 ng/ml, 90% in 71 with PSA 10.1-20 ng/ml, and 79% in 71 with PSA>20 ng/ml. These results are excellent comparable or superior to those of surgery. Thus, particle therapy is sophisticated radiotherapy, however the only problem to prohibit the progress is high costs for construction and maintenance. Facilities at which both proton and carbon ion beams can be used, including the HIBMC, have to investigate the differential use. We started clinical randomized trial to compare both ion beams, and started biological examinations in a project aiming at the development of a laser driven proton radiotherapy. We stated about the current status of the HIBMC and the results of representative diseases.},

  doi          = {10.1063/1.3204552},

  url          = {https://www.osti.gov/biblio/21344336},
  journal      = {AIP Conference Proceedings},

  issn         = {0094-243X},

  number       = 1,

  volume       = 1153,

  place        = {United States},

  year         = {Sat Jul 25 00:00:00 EDT 2009},

  month        = {Sat Jul 25 00:00:00 EDT 2009}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1063/1.3204552

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Current State Of Proton And Carbon-Ion Radiotherapy At The Hyogo Ion Beam Medical Center (HIBMC)

Journal Article Murakami, Masao; Hishikawa, Yoshio; Demizu, Yusuke; ... - AIP Conference Proceedings

HIBMC is the world's first facility to be able to use both proton (PRT) and carbon-ion radiotherapy (CiRT). The medically dedicated synchrotron can accelerate protons up to 230 MeV and carbon ions up to 320 MeV. From April 2001 to March 2010, the facility treated 3275 patients, with 2487 patients treated using PRT and 788 using CiRT. Particle radiotherapy was delivered to patients suffering from malignant tumors originating in the head and neck (502 patients), lungs (330), liver (539), prostate (1283), and the bone and soft tissue (130). The clinical results are as follows: (1) H and N tumors: Themore »« less
https://doi.org/10.1063/1.3586123
Comparison of biochemical failure definitions for permanent prostate brachytherapy

Journal Article Kuban, Deborah; Levy, Larry; Potters, Louis; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy. Methods and Materials: A total of 2,693 patients treated with radioisotopic implant as solitary treatment for T1-T2 prostatic adenocarcinoma were studied. All patients had a pretreatment PSA, were treated at least 5 years before analysis, 1988 to 1998, and did not receive hormonal therapy before recurrence. Multiple PSA failure definitions were tested for their ability to predict clinical failure. Results: Definitions which determined failure by a certain increment of PSA rise above the lowest PSA level to date (nadir +more »« less
https://doi.org/10.1016/j.ijrobp.2006.03.027
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Journal Article Feigenberg, Steven; Hanlon, Alexandra; Horwitz, Eric; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Several large randomized prospective studies have demonstrated a survival benefit with the addition of long-term androgen deprivation to definitive radiotherapy for patients with Gleason score 8-10 or T3-T4 prostate cancer. However, these studies were performed before the routine use of prostate-specific antigen (PSA) measurement. The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era. Methods and materials: The data set evaluated consisted of 1003 prostate cancer patients treated definitively with three-dimensional conformal radiotherapy between May 1, 1989 and November 30, 1999 (medianmore »« less
https://doi.org/10.1016/j.ijrobp.2004.07.725
Equivalent Biochemical Control and Improved Prostate-Specific Antigen Nadir After Permanent Prostate Seed Implant Brachytherapy Versus High-Dose Three-Dimensional Conformal Radiotherapy and High-Dose Conformal Proton Beam Radiotherapy Boost

Journal Article Jabbari, Siavash; Weinberg, Vivian; Shinohara, Katsuto; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Permanent prostate implant brachytherapy (PPI), three-dimensional conformal radiotherapy (3D-CRT), and conformal proton beam radiotherapy (CPBRT) are used in the treatment of localized prostate cancer, although no head-to-head trials have compared these modalities. We studied the biochemical control (biochemical no evidence of disease [bNED]) and prostate-specific antigen (PSA) nadir achieved with contemporary PPI, and evaluated it against 3D-CRT and CPBRT. Patients and Methods: A total of 249 patients were treated with PPI at the University of California, San Francisco, and the outcomes were compared with those from a 3D-CRT cohort and the published results of a high-dose CPBRT boost (CPBRTB)more »« less
https://doi.org/10.1016/j.ijrobp.2009.01.029
Redefining High-Risk Prostate Cancer Based on Distant Metastases and Mortality After High-Dose Radiotherapy With Androgen Deprivation Therapy

Journal Article Reddy, Chandana; Stephans, Kevin; Ciezki, Jay; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Modern outcomes of high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) for high-risk (HR) prostate cancer are not well described. Methods and Materials: We identified 585 patients who met HR criteria by 2010 National Comprehensive Cancer Network guidelines, who were treated with EBRT consisting of {>=}74 Gy from 1996 to 2008 at Cleveland Clinic, of whom 95% received ADT. We analyzed biochemical relapse-free survival (bRFS), distant metastases-free survival (DMFS), and prostate cancer-specific mortality (PCSM). Results: The median EBRT dose was 78 Gy, and median ADT duration was 6 months. At 10 years, the bRFS was 50.2%, themore »« less
https://doi.org/10.1016/J.IJROBP.2011.04.042

Similar Records